OncLive TV

Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.

Thomas Helleday, PhD, professor of Translational Oncology, director of the Weston Park Cancer Centre, Department of Oncology and Metabolism, The Medical School, The University of Sheffield, discusses the similarity of biosimilars and biologics.

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses the potential use of CDK4/6 inhibitors in HER2-positive breast cancer.

Charalambos (Babis) Andreadis, MD, MSCE, discusses the need to identify an optimal standard of care in patients with relapsed/refractory mantle cell lymphoma.

Alexander Leandros Lazarides, MD, discusses some of the current challenges in moving the field forward in osteosarcoma.

Hossein Borghaei, DO, MS, discusses immune-related adverse events in patients with lung cancer who received immunotherapy/chemotherapy combinations.

Ulka Vaishampayan, MD, professor of oncology at Wayne State University, and the chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the current role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Elisabeth I. Heath, MD, FACP, discusses the safety profiles of apalutamide, enzalutamide, and darolutamide in nonmetastatic castration-resistant prostate cancer.

Kathleen Moore, MD, director, Oklahoma TSET Phase I Program, and associate professor, Section of Gynecologic Oncology, Stephenson Cancer Center, discusses treatment for patients with ovarian cancer who progress on a PARP inhibitor.

Jennifer Woyach, MD, discusses frontline treatment options for patients with chronic lymphocytic leukemia.

Ulka Vaishampayan, MD, discusses trials that examine frontline immunotherapy for metastatic kidney cancer.

Thomas G. Martin, MD, discusses the impact of subcutaneous administration of daratumumab on patients with early relapse multiple myeloma.

Sandy Wong, MD, discusses investigational CAR T-cell products in relapsed/refractory multiple myeloma.

Mario Sznol, MD, discusses the management of patients with melanoma who progress on immune checkpoint inhibitors.

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Nabil P. Rizk, MD, MS, MPH, discusses the role of anatomic surgical resection in nonmetastatic lung cancer.

Rebecca L. Olin, MD, MSCE, associate professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the utility of venetoclax in acute myeloid leukemia.

Benjamin P. Levy, MD, discusses treatment options for patients with oncogenic-driven non–small cell lung cancer.

Sarah Crafton, MD, discusses the impact of PARP inhibitors on patients with recurrent ovarian cancer.

Bita Fakhri, MD, MPH, discusses the trials that led to ibrutinib-containing regimens becoming the standard of care for chronic lymphocytic leukemia over traditional chemotherapy options.

Tiffany A. Traina, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201) for patients with HER2-positive, locally advanced, or metastatic breast cancer who have been treated with trastuzumab (Herceptin) and pertuzumab (Perjeta) and have disease progression after ado-trastuzumab emtansine (T-DM1; Kadcyla).

Julie R. Gralow, MD, clinical director, Breast Medical Oncology, Seattle Cancer Care Alliance, professor, medical oncology, University of Washington School of Medicine, discusses the global impact of biosimilars in HER2-positive breast cancer.

Michel Vulfovich, MD, medical director, Sickle Cell Disease and Gynecology Oncology programs, Memorial Healthcare System, discusses the utility of broad molecular profiling in metastatic colorectal cancer (mCRC).

Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the potential cost effectiveness of a 12-month fixed duration of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) in first-line chronic lymphocytic leukemia (CLL).

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial in patients with previously untreated chronic lymphocytic leukemia.

Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.

Mira Hellmann, MD, gynecologic oncologist and assistant professor, John Theurer Cancer Center, Hackensack University Medical Center, discusses the use of sentinel lymph node mapping in patients with endometrial cancer.

Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.